Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 48Neoplasms 35Carcinoma, Non-Small-Cell Lung 30Colorectal Neoplasms 29Prostatic Neoplasms 27Lung Neoplasms 27Pancreatic Neoplasms 19Multiple Myeloma 15Recurrence 14Ovarian Neoplasms 14Uterine Cervical Neoplasms 12Neoplasm Metastasis 10Leukemia, Myeloid, Acute 10Brain Neoplasms 10Melanoma 9Head and Neck Neoplasms 9Carcinoma, Hepatocellular 9Stomach Neoplasms 8Rectal Neoplasms 8Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Small Cell Lung Carcinoma 7Glioblastoma 7Endometrial Neoplasms 7Advanced Solid Tumors 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Glioma 6Esophageal Neoplasms 6Colonic Neoplasms 6Carcinoma, Renal Cell 6

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Tongue Neoplasms × 30 days × Clear all
NCT07552558 2026-06-03

Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

Washington University School of Medicine

Phase 1/2 Not yet recruiting
45 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Jaw Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡